{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreia2mcdhr2rqfovygrgu4r435a2ggauvj2iy4qygdvqibldu5pudy4",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mgswh4cso5i2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicubcmbaogofgr2hzukmwv3ivcfexmz5l7qxj36tuo2r5gcvgthfu"
    },
    "mimeType": "image/jpeg",
    "size": 71015
  },
  "path": "/news/2026-03-dengue-vaccine-effective-severe-cases.html",
  "publishedAt": "2026-03-11T17:10:09.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "In a phase 3 clinical trial, the tetravalent dengue vaccine, developed by the Butantan Institute in São Paulo, Brazil, was 80.5% effective against severe dengue cases with warning signs over a five-year period. The results of the trial are published in Nature Medicine.",
  "title": "Dengue vaccine remains 80.5% effective against severe cases after five years"
}